Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 0.2424
-0.0048 (-1.94%)
Jun 17, 2025, 12:59 PM CET
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 277.89 | 198.72 | 238.73 | 57.62 | 10.71 | - | Upgrade
|
| Revenue | 277.89 | 198.72 | 238.73 | 57.62 | 10.71 | - | Upgrade
|
| Revenue Growth (YoY) | 45.52% | -16.76% | 314.33% | 438.03% | - | - | Upgrade
|
| Cost of Revenue | 53.77 | 18.23 | 203.34 | - | - | - | Upgrade
|
| Gross Profit | 224.12 | 180.5 | 35.39 | 57.62 | 10.71 | - | Upgrade
|
| Selling, General & Admin | 39.92 | 40.11 | 40.03 | 31.54 | 31.4 | 26.51 | Upgrade
|
| Research & Development | 259.6 | 312.89 | 305.78 | 199.65 | 160.62 | 197.28 | Upgrade
|
| Other Operating Expenses | 27 | 30.54 | -13.71 | -20.91 | -4.85 | -7.14 | Upgrade
|
| Operating Expenses | 326.51 | 383.54 | 332.11 | 210.27 | 187.17 | 216.65 | Upgrade
|
| Operating Income | -102.39 | -203.04 | -296.72 | -152.65 | -176.46 | -216.65 | Upgrade
|
| Interest Expense | -30.9 | -33.63 | -18.5 | -2.58 | -2.64 | -0.69 | Upgrade
|
| Interest & Investment Income | 0.5 | 0.5 | 2.41 | 0.3 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -14.03 | -14.87 | -9.15 | -13.56 | -4.13 | -0.79 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.39 | -2.39 | -0.06 | -0.01 | -0.01 | - | Upgrade
|
| Pretax Income | -149.21 | -253.43 | -322.03 | -168.51 | -183.23 | -218.13 | Upgrade
|
| Income Tax Expense | 11.59 | 11.59 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -160.8 | -265.02 | -322.03 | -168.51 | -183.23 | -218.13 | Upgrade
|
| Earnings From Discontinued Operations | 0.15 | -1.2 | -66.14 | -4 | -5.15 | -7.9 | Upgrade
|
| Net Income | -160.65 | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 | Upgrade
|
| Net Income to Common | -160.65 | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 | Upgrade
|
| Shares Outstanding (Basic) | 1,532 | 1,230 | 29 | 26 | 24 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 1,532 | 1,230 | 29 | 26 | 24 | 18 | Upgrade
|
| Shares Change (YoY) | 1387.44% | 4184.96% | 12.26% | 8.38% | 30.25% | 61.86% | Upgrade
|
| EPS (Basic) | -0.10 | -0.22 | -13.52 | -6.75 | -7.98 | -12.48 | Upgrade
|
| EPS (Diluted) | -0.11 | -0.22 | -13.52 | -6.75 | -7.99 | -12.48 | Upgrade
|
| Free Cash Flow | -89.16 | -134.23 | -413.47 | -205.53 | -247.29 | -242.26 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.11 | -14.40 | -8.04 | -10.48 | -13.38 | Upgrade
|
| Gross Margin | 80.65% | 90.83% | 14.82% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -36.84% | -102.17% | -124.29% | -264.94% | -1647.75% | - | Upgrade
|
| Profit Margin | -57.81% | -133.97% | -162.60% | -299.41% | -1759.04% | - | Upgrade
|
| Free Cash Flow Margin | -32.09% | -67.55% | -173.20% | -356.72% | -2309.16% | - | Upgrade
|
| EBITDA | -93.31 | -193.86 | -287.62 | -145.21 | -171.93 | -214.07 | Upgrade
|
| EBITDA Margin | -33.58% | -97.55% | -120.48% | -252.03% | - | - | Upgrade
|
| D&A For EBITDA | 9.08 | 9.18 | 9.1 | 7.44 | 4.53 | 2.57 | Upgrade
|
| EBIT | -102.39 | -203.04 | -296.72 | -152.65 | -176.46 | -216.65 | Upgrade
|
| EBIT Margin | -36.84% | -102.17% | -124.29% | -264.94% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.